Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

19.1%

9 terminated out of 47 trials

Success Rate

71.0%

-15.5% vs benchmark

Late-Stage Pipeline

4%

2 trials in Phase 3/4

Results Transparency

32%

7 of 22 completed with results

Key Signals

7 with results71% success

Data Visualizations

Phase Distribution

37Total
Not Applicable (4)
Early P 1 (4)
P 1 (17)
P 2 (10)
P 3 (1)
P 4 (1)

Trial Status

Completed22
Terminated9
Active Not Recruiting5
Recruiting4
Unknown3
Enrolling By Invitation2

Trial Success Rate

71.0%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT05104723Phase 1CompletedPrimary

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT02116764CompletedPrimary

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

NCT07284641Phase 2Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT05463133Phase 1RecruitingPrimary

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

NCT02108028Completed

Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer

NCT03910452Early Phase 1Active Not RecruitingPrimary

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT00368446Completed

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT03645486Not ApplicableRecruitingPrimary

Lentiviral Gene Therapy for CGD

NCT05189925Phase 1RecruitingPrimary

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

NCT06253507Phase 1Enrolling By Invitation

pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

NCT01821781Phase 2Active Not Recruiting

Immune Disorder HSCT Protocol

NCT01652092Not ApplicableActive Not Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT03983837Phase 2CompletedPrimary

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease

NCT00778882Phase 1WithdrawnPrimary

Gene Therapy for Chronic Granulomatous Disease in Korea

NCT05600907Early Phase 1Active Not RecruitingPrimary

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

NCT05687474Completed

Baby Detect : Genomic Newborn Screening

NCT03333486Phase 2Terminated

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

NCT06559176Phase 1Active Not RecruitingPrimary

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

NCT03655223Enrolling By Invitation

Early Check: Expanded Screening in Newborns

NCT05915897TerminatedPrimary

Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

Scroll to load more

Research Network

Activity Timeline